4 ms·

What are you on about? They're actively testing Sorrento's treatment, yes (it's not 'a cure'; it -is- a treatment for those in the ICU. It's an infusion). This

What are you on about? They're actively testing Sorrento's treatment, yes (it's not 'a cure'; it -is- a treatment for those in the ICU. It's an infusion). This pill is also 'bogged down by testing'; if testing is successful it will be available later this year. Sorrento's treatment is going into phase 2; this pill is just entering phase 1. Sorrento also got $34 million from DARPA for their treatment, I might add. Is this just a general "Rargh, drugs shouldn't take so much testing!" complaint, or are you asserting that Pfizer, Moderna, and J&J are getting preferential treatment that Sorrento isn't?

brightball 6y ago
From what I have been reading, it’s saved the lives of everybody who it’s been given to so far but I haven’t seen much coverage of it outside of the stock reports. Just struck me as odd that it’s bogged down in more testing when it seems to have a near perfect record. Blows my mind that India and Brazil aren’t begging for it considering the scope of their current situations. After following it for the last year, suddenly seeing the Pfizer option out of nowhere just struck me as odd.
- perardi 6y ago
  You better have an actual citation for this miracle drug. Because this sounds a bit like remdesivir, one of the earlier candidates for a savior drug that, once we had more statistical power, didn’t really pan out. https://www.nejm.org/doi/full/10.1056/nejmoa2007764 https://www.nejm.org/doi/full/10.1056/nejmoa2007764 Also, if it’s an IV infusion, in a poorer country with a massively strained health care system…well, good luck actually deploying it.
  - lostcolony 6y ago
    A little of both really. While no one it's been administered to has died, it's not been administered to many people, and it has been administered without control. Which isn't shocking; that's the first phase of human testing, just see if it seems to actually help, and not create issues itself. They're setting up for tests with a control group next. https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-announces-updated-positive-results-phase-1b-study-covi https://investors.sorrentotherapeutics.com/news-releases/new... It could indeed fizzle like Remdesivir. Just, yeah, the data, while promising, is so small it tells us nothing. Hence why the clinical trial process.
    - perardi 6y ago
      Thank you for linking to the actual drug, versus the inscrutable parent comment. And from that link… “All nine patients…” …and from the parent… “it’s saved the lives of everybody who it’s been given to so far” Well, when N=9, whoop-dee-doo. Also, while that sure could be promising, color me quite surprised if they can up human-derived stem cells to treat a surge like they are seeing in India.

brightball 6y ago

From what I have been reading, it’s saved the lives of everybody who it’s been given to so far but I haven’t seen much coverage of it outside of the stock reports. Just struck me as odd that it’s bogged down in more testing when it seems to have a near perfect record. Blows my mind that India and Brazil aren’t begging for it considering the scope of their current situations. After following it for the last year, suddenly seeing the Pfizer option out of nowhere just struck me as odd.

perardi 6y ago
You better have an actual citation for this miracle drug. Because this sounds a bit like remdesivir, one of the earlier candidates for a savior drug that, once we had more statistical power, didn’t really pan out. https://www.nejm.org/doi/full/10.1056/nejmoa2007764 https://www.nejm.org/doi/full/10.1056/nejmoa2007764 Also, if it’s an IV infusion, in a poorer country with a massively strained health care system…well, good luck actually deploying it.
- lostcolony 6y ago
  A little of both really. While no one it's been administered to has died, it's not been administered to many people, and it has been administered without control. Which isn't shocking; that's the first phase of human testing, just see if it seems to actually help, and not create issues itself. They're setting up for tests with a control group next. https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-announces-updated-positive-results-phase-1b-study-covi https://investors.sorrentotherapeutics.com/news-releases/new... It could indeed fizzle like Remdesivir. Just, yeah, the data, while promising, is so small it tells us nothing. Hence why the clinical trial process.
  - perardi 6y ago
    Thank you for linking to the actual drug, versus the inscrutable parent comment. And from that link… “All nine patients…” …and from the parent… “it’s saved the lives of everybody who it’s been given to so far” Well, when N=9, whoop-dee-doo. Also, while that sure could be promising, color me quite surprised if they can up human-derived stem cells to treat a surge like they are seeing in India.